8-K

MILESTONE SCIENTIFIC INC. (MLSS)

8-K 2022-01-20 For: 2022-01-20
View Original
Added on April 06, 2026

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): January 20, 2022

Milestone Scientific Inc.

(Exact name of registrant as specified in its charter)

Delaware 001-14053 13-3545623
(State or other jurisdiction<br> of incorporation) (Commission<br> File Number) (IRS Employer<br> Identification No.)
425 Eagle Rock Avenue<br><br> <br>Suite 403 <br> Roseland, New Jersey<br> (Address of principal executive offices) 07068<br> (Zip Code)
--- ---

Registrant’s telephone number, including area code (973) 535-2717

(Former name or former address, if changed since last report.)

Securities registered pursuant to Section 12(b) of the Act:

Title of each class Trading Symbol(s) Name on exchange on which registered
Common Stock MLSS NYSE American

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instructions A.2. below):

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act ☐


Item 7.01         Regulation FD Disclosure

Arjan Haverhals, President and Chief Executive Officer of Milestone Scientific Inc. (the “Company”), in an interview on January 20, 2022, beginning at 11 a.m. EST with Anthony Vendetti, executive managing director of research at Maxim Group LLC, accessible at Fireside Chat with Milestone Scientific, Inc. (MLSS) | M-Vest, stated that the Company had in excess of $14 million in cash and cash equivalents on hand at the end of 2021, and further disclosed that such amount is substantially equivalent to the cash on hand at the end of 2020.  Mr. Haverhals further confirmed that the Company continues to have sufficient liquidity to support its operations for another 2 years.


SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

MILESTONE SCIENTIFIC INC.
Dated: January 20, 2022 By: /s/ Arjan Haverhals
Arjan Haverhals,
Chief Executive Officer